SERM


Also found in: Dictionary, Acronyms, Encyclopedia, Wikipedia.

modulator

 [mod´u-la″ter]
a specific inductor or agent that brings out characteristics peculiar to a definite region.
selective estrogen receptor modulator (SERM) an agent that activates some estrogen receptors but not others, thereby having estrogenlike effects on target tissues (such as bone) without affecting other tissues that have estrogen receptors.

SERM

SERM

abbr.
selective estrogen receptor modulator

SERM

SERM

Selective estrogen receptor modulator, see there.

SERM

Abbreviation for selective estrogen receptor modulator.
References in periodicals archive ?
The USPSTF review of seven large randomized controlled trials evaluating women without preexisting breast cancer showed that SERMs can be utilized to decrease the incidence of invasive breast cancer in postmenopausal women by 30%-55%, or 7-9 fewer events per 1,000 in a 5-year period.
To measure non-adherence to therapy, we identified the subset of sample members who had at least one PDE record for SERM or AI and who had at least 12 consecutive months of Part D enrollment following the first filled prescription for either drug.
Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women.
Two other SERMs have been developed--lasofoxifene and arzoxifene.
Therefore SERMs appear to be a good substitute for progestin.
While it is true that Osphena has not been studied in such women, the class effect of all SERMs in addition to the basic science data speak for themselves.
For example, drugs used to treat hypertension and lower cholesterol, both markers of coronary artery disease, have more adverse effects--and more serious ones--than SERMs do.
Like other SERMs, lasofoxifene raises the risk of venous thromboembolism and increases the rate of hot flushes and leg cramps, wrote Dr.
Arzoxifene is a benzothiophene-class SERM, like raloxifene, which is approved in postmenopausal women for the treatment and prevention of osteoporosis as well as for invasive breast cancer risk reduction in such women who are at high risk for the cancer or who have osteoporosis.
He reported being an investigator in a study of a SERM manufactured by Wyeth Pharmaceuticals.
As expected, the SERM had no effect on the rate of estrogen receptor-negative breast cancers.
Lise Warming, a researcher who studied the SERM for the Center for Clinical and Basic Research in Ballerup, Denmark, called the levormeloxifene story "disturbing.